A Phase 2 interventional study of LY2452473 and tadalafil in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 36 sites in United States. Open to male participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-04-09.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.
Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 13th largest by enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2010, is one of 4 in phase 2, and was the 29th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Surgical Outcomes Research Centre (SOuRCe) · Sites in Australia
Ages 18+ · Men only
Al-Azhar University · Sites in Egypt
Ages 18–70 · Men only
Beni-Suef University · Sites in Egypt
Ages 30–70 · Men only
Mansoura University · Sites in Egypt
Ages 21+ · Men only
Aswan University Hospital · Sites in Egypt
Ages 21+ · Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 45 Years to 70 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 21 · Phase 4 26
First in 2002; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 410 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 199 across the 56 interventional studies. Of the 42 that completed or were terminated, 13 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 57 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
28 studies in Erectile Dysfunction by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 28 finished, 14 (50%) have results posted.
Among the 28 studies in Erectile Dysfunction by Eli Lilly and Company, this one is the 11th largest by enrollment, is one of 3 that started in 2010, is one of 2 in phase 2, and was the 23rd registered.
Eli Lilly and Company’s Erectile Dysfunction studies by the year they started, since 2002.
3 of the studies testing tadalafil in Erectile Dysfunction that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07642505Beni-Suef UniversityL-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction | 2026-11 |
| NCT07391579Mansoura UniversityDaily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients | 2026-12 |
| NCT07753720Al-Azhar UniversityDaily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies testing tadalafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 28 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to compare the efficacy of LY2452473 + tadalafil to tadalafil alone in improving the erectile function (EF) of men with erectile dysfunction (ED) who incompletely respond to tadalafil alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LY2452473 · Drug: tadalafil · Drug: placebo (tadalafil)
Drug: LY2452473 · Drug: tadalafil · Drug: placebo (tadalafil)
Drug: LY2452473 · Drug: placebo (tadalafil)
Drug: tadalafil · Drug: placebo (tadalafil) · Drug: placebo (LY2452473)
Drug: tadalafil · Drug: placebo (tadalafil) · Drug: placebo (LY2452473)
Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain Score
The IIEF EF domain score was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF self-reported questionnaire. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in the Percentage of "Yes" Responses on the Sexual Encounter Profile (SEP) Diary
The SEP diary was a participant-assessed diary with 5 questions (Q): Q1 (erection achievement), Q2 (successful penetration), Q3 (successful intercourse), Q4 (satisfied with erection), and Q5 (satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1 to Q5 scores were determined as a percentage of "Yes" responses to each of the 5 questions out of all sexual attempts recorded during the time period. A higher percentage of "Yes" responses indicated better EF. Assessed was the mean change from baseline in the percentage of "Yes" responses to the SEP diary Q1 to Q5. The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value \<0.25).
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in IIEF Domain Scores (Intercourse Satisfaction, Orgasmic Function, Sexual Desire, and Overall Satisfaction)
Intercourse Satisfaction (IS) domain score: sum of Questions (Q) 6, Q7, and Q8, each rated 0 (low/no satisfaction) to 5 (high satisfaction). IS domain score range: 0 to 15; lower scores denoted lower satisfaction. Orgasmic Function (OF) domain score: sum of Q9 and Q10, each rated 0 (no sexual stimulation) to 5 (almost always/always). OF domain score range: 0 to 10; lower scores denoted lower OF. Sexual Desire (SD) domain score: sum of Q11 and Q12, each rated 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). SD domain score range: 2 to 10; lower scores denoted lower SD. Overall Satisfaction (OS) domain score: sum of Q13 and Q14, each rated 1 (low/no satisfaction) to 5 (high satisfaction). OS domain score range: 2 to 10; lower scores denoted lower OS. Least squares (LS) mean estimated from repeated measures analysis of variance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value\<0.25).
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in the Percentage of Participants Who Return to "Normal" on the International Index of Erectile Function (IIEF) Scale (EF>25)
The percentage of participants whose IIEF Erectile Function (EF) domain scores changed from ≤25 at baseline to \>25 (normal) at Week 12. The IIEF EF domain score was the sum of IIEF Question (Q) 1 to Q5 and Q15. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in IIEF EF Domain Score Reported by Testosterone Concentration Subgroups
The International Index of Erectile Function (IIEF) EF was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF Self-reported questionnaire. Q1 to Q5 were rated 0 (low/no erectile function) to 5 (high erectile function) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF. Testosterone concentration subgroups were based on optimal baseline testosterone levels (\<340 nanograms per deciliter \[ng/dL\] or ≥340 ng/dL). The least squares (LS) mean was estimated from an analysis of covariance (ANCOVA) model that included terms for treatment group, baseline, and baseline\*treatment interaction (if p-value\<0.25).
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in Prostate-Specific Antigen (PSA)
The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value\<0.25).
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in Total Cholesterol and Triglycerides
The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value\<0.25).
Time frame: Baseline, Week 12
Percent Change From Baseline to 12 Week Endpoint in High-Density Lipoprotein Cholesterol (HDL-C) and Low-Density Lipoprotein Cholesterol (LDL-C)
The least squares (LS) was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value\<0.25).
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in Fasting Glucose
The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value\<0.25).
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in Fasting Insulin
Change from baseline to 12 Week endpoint in fasting blood insulin concentration. The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value\<0.25).
Time frame: Baseline, Week 12
| Milestone | All Screened Subjects | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|---|
| Started | 894 | 0 | 0 | 0 | 0 | 0 |
| Completed | 410 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 484 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 8 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Entry criteria not met | 308 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 9 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 26 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomization criteria not met | 67 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 64 | 0 | 0 | 0 | 0 | 0 |
| Milestone | All Screened Subjects | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|---|
| Started | 0 | 85 | 97 | 52 | 89 | 87 |
| Received at least 1 dose of study drug | 0 | 85 | 97 | 52 | 89 | 87 |
| Completed | 0 | 65 | 73 | 31 | 80 | 73 |
| Not completed | 0 | 20 | 24 | 21 | 9 | 14 |
| Withdrew: Adverse event | 0 | 4 | 4 | 2 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 | 2 | 5 | 3 | 4 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 4 | 2 | 0 | 1 | 3 |
| Withdrew: Withdrawal by subject | 0 | 5 | 13 | 8 | 5 | 7 |
| Withdrew: Entry criteria not met | 0 | 2 | 2 | 2 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 1 | 0 | 0 | 0 | 0 |
The IIEF EF domain score was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF self-reported questionnaire. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.
| units on a scale | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|
| Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain Score | 2.515 ± 6.019 | 2.405 ± 6.920 | -0.971 ± 6.699 | 3.530 ± 5.640 | 2.054 ± 4.800 |
The SEP diary was a participant-assessed diary with 5 questions (Q): Q1 (erection achievement), Q2 (successful penetration), Q3 (successful intercourse), Q4 (satisfied with erection), and Q5 (satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1 to Q5 scores were determined as a percentage of "Yes" responses to each of the 5 questions out of all sexual attempts recorded during the time period. A higher percentage of "Yes" responses indicated better EF. Assessed was the mean change from baseline in the percentage of "Yes" responses to the SEP diary Q1 to Q5. The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value \<0.25).
| percentage of "yes" responses | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|
| Question 1 | -0.247 ± 2.378 | -2.976 ± 2.295 | -10.711 ± 3.268 | 4.427 ± 2.168 | -1.425 ± 2.305 |
| Question 2 | 3.175 ± 3.345 | 3.689 ± 3.227 | -7.849 ± 4.566 | 10.267 ± 3.064 | 1.844 ± 3.240 |
| Question 3 | 9.296 ± 3.808 | 11.752 ± 3.675 | -3.800 ± 5.195 | 14.645 ± 3.489 | 2.593 ± 3.688 |
| Question 4 | 12.935 ± 3.998 | 13.910 ± 3.854 | -1.570 ± 5.454 | 24.202 ± 3.656 | 8.857 ± 3.872 |
| Question 5 | 13.602 ± 4.027 | 15.196 ± 3.880 | -1.956 ± 5.488 | 22.410 ± 3.683 | 9.400 ± 3.897 |
Intercourse Satisfaction (IS) domain score: sum of Questions (Q) 6, Q7, and Q8, each rated 0 (low/no satisfaction) to 5 (high satisfaction). IS domain score range: 0 to 15; lower scores denoted lower satisfaction. Orgasmic Function (OF) domain score: sum of Q9 and Q10, each rated 0 (no sexual stimulation) to 5 (almost always/always). OF domain score range: 0 to 10; lower scores denoted lower OF. Sexual Desire (SD) domain score: sum of Q11 and Q12, each rated 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). SD domain score range: 2 to 10; lower scores denoted lower SD. Overall Satisfaction (OS) domain score: sum of Q13 and Q14, each rated 1 (low/no satisfaction) to 5 (high satisfaction). OS domain score range: 2 to 10; lower scores denoted lower OS. Least squares (LS) mean estimated from repeated measures analysis of variance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value\<0.25).
| units on a scale | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|
| Intercourse Satisfaction | 0.475 ± 0.340 | 0.514 ± 0.322 | -0.672 ± 0.463 | 1.127 ± 0.310 | 0.554 ± 0.327 |
| Orgasmic Function | 0.510 ± 0.289 | 0.117 ± 0.274 | 0.160 ± 0.394 | 0.678 ± 0.264 | 0.733 ± 0.278 |
| Sexual Desire | 0.092 ± 0.186 | 0.001 ± 0.176 | -0.201 ± 0.253 | 0.392 ± 0.169 | 0.180 ± 0.178 |
| Overall Satisfaction | 0.477 ± 0.247 | 0.258 ± 0.235 | -0.378 ± 0.339 | 1.206 ± 0.226 | 0.826 ± 0.238 |
The percentage of participants whose IIEF Erectile Function (EF) domain scores changed from ≤25 at baseline to \>25 (normal) at Week 12. The IIEF EF domain score was the sum of IIEF Question (Q) 1 to Q5 and Q15. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.
| percentage of participants | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|
| Change From Baseline to 12 Week Endpoint in the Percentage of Participants Who Return to "Normal" on the International Index of Erectile Function (IIEF) Scale (EF>25) | 24.7 | 27.8 | 13.5 | 30.3 | 27.6 |
The International Index of Erectile Function (IIEF) EF was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF Self-reported questionnaire. Q1 to Q5 were rated 0 (low/no erectile function) to 5 (high erectile function) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF. Testosterone concentration subgroups were based on optimal baseline testosterone levels (\<340 nanograms per deciliter \[ng/dL\] or ≥340 ng/dL). The least squares (LS) mean was estimated from an analysis of covariance (ANCOVA) model that included terms for treatment group, baseline, and baseline\*treatment interaction (if p-value\<0.25).
| units on a scale | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|
| Testosterone <340 ng/dL | 2.523 ± 0.952 | 1.012 ± 0.848 | -1.055 ± 1.223 | 4.172 ± 0.852 | 1.935 ± 0.912 |
| Testosterone ≥340 ng/dL | 1.077 ± 1.019 | 3.416 ± 1.071 | -0.714 ± 1.387 | 2.217 ± 1.070 | 1.703 ± 1.063 |
The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value\<0.25).
| nanograms per milliliter (ng/mL) | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|
| Change From Baseline to 12 Week Endpoint in Prostate-Specific Antigen (PSA) | 0.162 ± 0.119 | -0.088 ± 0.109 | 0.265 ± 0.157 | 0.246 ± 0.107 | 0.032 ± 0.111 |
The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value\<0.25).
| millimoles per Liter (mmol/L) | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|
| Total Cholesterol | -0.210 ± 0.076 | -0.275 ± 0.071 | -0.282 ± 0.102 | -0.086 ± 0.069 | -0.059 ± 0.072 |
| Triglycerides | -0.155 ± 0.070 | -0.171 ± 0.066 | -0.067 ± 0.096 | -0.139 ± 0.063 | 0.056 ± 0.067 |
The least squares (LS) was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value\<0.25).
| percent change | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|
| HDL-C | -7.440 ± 1.658 | -16.974 ± 1.556 | -22.230 ± 2.243 | 1.776 ± 1.505 | 1.573 ± 1.585 |
| LDL-C | -1.695 ± 2.479 | 0.062 ± 2.319 | -3.424 ± 3.365 | -0.066 ± 2.245 | -0.718 ± 2.367 |
The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value\<0.25).
| millimoles per Liter (mmol/L) | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|
| Change From Baseline to 12 Week Endpoint in Fasting Glucose | 0.153 ± 0.195 | -0.306 ± 0.183 | 0.070 ± 0.268 | -0.234 ± 0.176 | 0.158 ± 0.186 |
Change from baseline to 12 Week endpoint in fasting blood insulin concentration. The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment\*visit, baseline, baseline\*treatment (if p-value\<0.25).
| milliunits per Liter (mU/L) | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|
| Change From Baseline to 12 Week Endpoint in Fasting Insulin | 3.756 ± 2.235 | -4.501 ± 2.075 | -0.717 ± 3.068 | -3.300 ± 1.976 | -1.276 ± 2.109 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5 mg Tadalafil, Lead-in Period | — | 2/531 (0.4%) | 88/531 (16.6%) |
| 1 mg LY2452473 and 5 mg Tadalafil | — | 2/85 (2.4%) | 27/85 (31.8%) |
| 5 mg LY2452473 and 5 mg Tadalafil | — | 1/97 (1%) | 23/97 (23.7%) |
| 5 mg LY2452473 | — | 1/52 (1.9%) | 10/52 (19.2%) |
| 10 mg Tadalafil | — | 0/89 (0%) | 34/89 (38.2%) |
| 5 mg Tadalafil | — | 0/87 (0%) | 33/87 (37.9%) |
| Event | 5 mg Tadalafil, Lead-in Period | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|---|
| Cardiac arrestCardiac disorders | 0/531 | 0/85 | 0/97 | 1/52 | 0/89 | 0/87 |
| Lobar pneumoniaInfections and infestations | 0/531 | 1/85 | 0/97 | 0/52 | 0/89 | 0/87 |
| Humerus fractureInjury, poisoning and procedural complications | 0/531 | 1/85 | 0/97 | 0/52 | 0/89 | 0/87 |
| Tubulointerstitial nephritisRenal and urinary disorders | 0/531 | 1/85 | 0/97 | 0/52 | 0/89 | 0/87 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/531 | 1/85 | 0/97 | 0/52 | 0/89 | 0/87 |
| ArrhythmiaCardiac disorders | 1/531 | 0/85 | 1/97 | 0/52 | 0/89 | 0/87 |
| Hypertensive cardiomyopathyCardiac disorders | 1/531 | 0/85 | 0/97 | 0/52 | 0/89 | 0/87 |
| Event | 5 mg Tadalafil, Lead-in Period | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil |
|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/531 | 1/85 | 2/97 | 0/52 | 4/89 | 3/87 |
| Urinary tract infectionInfections and infestations | 0/531 | 0/85 | 0/97 | 2/52 | 0/89 | 1/87 |
| NasopharyngitisInfections and infestations | 5/531 | 3/85 | 1/97 | 1/52 | 0/89 | 0/87 |
| Back painMusculoskeletal and connective tissue disorders | 4/531 | 3/85 | 1/97 | 0/52 | 3/89 | 1/87 |
| HeadacheNervous system disorders | 9/531 | 3/85 | 1/97 | 0/52 | 3/89 | 2/87 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 7/531 | 0/85 | 1/97 | 0/52 | 3/89 | 2/87 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/531 | 1/85 | 2/97 | 1/52 | 3/89 | 0/87 |
| PneumoniaInfections and infestations | 0/531 | 2/85 | 0/97 | 0/52 | 0/89 | 0/87 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/531 | 2/85 | 0/97 | 0/52 | 0/89 | 0/87 |
| DizzinessNervous system disorders | 3/531 | 2/85 | 1/97 | 0/52 | 2/89 | 0/87 |
All randomized participants.
| Age, Continuous(years) | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil | Total |
|---|---|---|---|---|---|---|
| Mean | 59.7 ± 6.57 | 60.7 ± 6.57 | 58.7 ± 6.53 | 59.4 ± 6.54 | 60.5 ± 6.68 | 59.9 ± 6.59 |
| Sex: Female, Male(Participants) | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 85 | 97 | 52 | 89 | 87 | 410 |
| Ethnicity (NIH/OMB)(Participants) | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 13 | 3 | 13 | 10 | 48 |
| Not Hispanic or Latino | 76 | 84 | 49 | 76 | 77 | 362 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 0 | 2 | 0 | 5 |
| Asian | 2 | 2 | 0 | 2 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 14 | 17 | 7 | 13 | 8 | 59 |
| White | 68 | 76 | 45 | 72 | 78 | 339 |
| More than one race | 0 | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 1 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 and 5 mg Tadalafil | 5 mg LY2452473 | 10 mg Tadalafil | 5 mg Tadalafil | Total |
|---|---|---|---|---|---|---|
| United States | 85 | 97 | 52 | 89 | 87 | 410 |
The record gives a start of Oct 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2019, 7 years 5 months after primary completion. A results delay was requested in Feb 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: LY2452473 · Tadalafil